» Articles » PMID: 38497438

Adverse Effects of Aldosterone: Beyond Blood Pressure

Overview
Date 2024 Mar 18
PMID 38497438
Authors
Affiliations
Soon will be listed here.
Abstract

Aldosterone is a steroid hormone that primarily acts through activation of the mineralocorticoid receptor (MR), a nuclear receptor responsible for downstream genomic regulation. Classically, activation of the MR in the renal tubular epithelium is responsible for sodium retention and volume expansion, raising systemic blood pressure. However, activation of the MR across a wide distribution of tissue types has been implicated in multiple adverse consequences for cardiovascular, cerebrovascular, renal, and metabolic disease, independent of blood pressure alone. Primary aldosteronism, heart failure, and chronic kidney disease are states of excessive aldosterone production and MR activity where targeting MR activation has had clinical benefits out of proportion to blood pressure lowering. The growing list of established and emerging therapies that target aldosterone and MR activation may provide new opportunities to improve clinical outcomes and enhance cardiovascular and renal health.

Citing Articles

The role of estrogen in the sex difference for the risk factors of heart failure with preserved ejection fraction.

Du J, Liu J, Wang X, Wang X, Ma Y, Zhang S Biol Direct. 2025; 20(1):28.

PMID: 40065410 PMC: 11895175. DOI: 10.1186/s13062-025-00618-x.


Epigenetic Regulation of the Renin-Angiotensin-Aldosterone System in Hypertension.

Takeda Y, Demura M, Yoneda T, Takeda Y Int J Mol Sci. 2024; 25(15).

PMID: 39125667 PMC: 11312206. DOI: 10.3390/ijms25158099.

References
1.
Rossignol P, Menard J, Fay R, Gustafsson F, Pitt B, Zannad F . Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and.... J Am Coll Cardiol. 2011; 58(19):1958-66. DOI: 10.1016/j.jacc.2011.04.049. View

2.
Rossignol P, Cleland J, Bhandari S, Tala S, Gustafsson F, Fay R . Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation. 2011; 125(2):271-9. DOI: 10.1161/CIRCULATIONAHA.111.028282. View

3.
Agarwal R, Rossignol P, Romero A, Garza D, Mayo M, Warren S . Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019; 394(10208):1540-1550. DOI: 10.1016/S0140-6736(19)32135-X. View

4.
Beygui F, Cayla G, Roule V, Roubille F, Delarche N, Silvain J . Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial. J Am Coll Cardiol. 2016; 67(16):1917-27. DOI: 10.1016/j.jacc.2016.02.033. View

5.
Redheuil A, Blanchard A, Pereira H, Raissouni Z, Lorthioir A, Soulat G . Aldosterone-Related Myocardial Extracellular Matrix Expansion in Hypertension in Humans: A Proof-of-Concept Study by Cardiac Magnetic Resonance. JACC Cardiovasc Imaging. 2020; 13(10):2149-2159. DOI: 10.1016/j.jcmg.2020.06.026. View